[The value of serum alpha-L-fucosidase activity in the diagnosis of primary liver cancer].
OBJECTIVE
To analyse the value of serum alpha-L-fucosidase (AFU) in the diagnosis of primary liver cancer (PLC).


METHODS
Serum AFU was studied in 141 patients with PLC, 17 patients with secondary liver cancer, 16 patients with cirrhosis, and 30 controls. Rank correlation analysis was used to assess the relation between value of AFU activity and TNM staging. The results were compared to those of serum AFP determination.


RESULTS
AFU was increased in 108 of 141 (76.6%) patients. The positive rate was statistically different from that in patients with secondary liver cancer, cirrhosis, and that in normal individual. The AFU level was correlated with TNM stage. In 25 PLC patients with AFU > 500 nmol.L-1.S-1, the average survival time was only 71 days. In 36 PLC patients who had received effective treatment, the serum AFU decreased to a significantly lower level than that examined before treatment. The positive rate of AFP in PLC patients was 64.5%. It rose to 86.2% if both parameters were used.


CONCLUSIONS
AFU is a useful marker of PLC for diagnosis and posttreatment monitoring.
Wei
X
X
Post and Telecomunications General Hospital, Institute of Liver Cancer, Beijing 100032, China.
Wang
S
S
Rui
J
J
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D005644:alpha-L-Fucosidase / Q000097:blood*
D014408:Biomarkers, Tumor; D005644:alpha-L-Fucosidase